62176-31-2

Usage

Uses

Used in Organic Synthesis:
2-BENZYLOXY-5-BROMO-BENZOIC ACID is used as a building block in organic synthesis for the creation of more complex molecules. Its unique structure and functional groups allow for various chemical reactions, enabling the synthesis of a wide range of compounds with diverse properties and applications.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-BENZYLOXY-5-BROMO-BENZOIC ACID is utilized as a key intermediate in the development of new pharmaceutical products. Its potential biological activities and compatibility with other molecules make it a promising candidate for the design and synthesis of novel drugs with improved therapeutic effects.
Used in Medicinal Chemistry:
2-BENZYLOXY-5-BROMO-BENZOIC ACID is of interest in medicinal chemistry due to its potential biological activities. Researchers are exploring its interactions with biological targets and evaluating its efficacy in treating various diseases. 2-BENZYLOXY-5-BROMO-BENZOIC ACID's unique structure and properties make it a valuable tool in the discovery and development of new therapeutic agents.
Used in Chemical Industry:
In the chemical industry, 2-BENZYLOXY-5-BROMO-BENZOIC ACID is employed in the production of various chemical products. Its versatility and reactivity make it a valuable component in the synthesis of a wide range of compounds, contributing to the development of new materials and technologies.
Overall, 2-BENZYLOXY-5-BROMO-BENZOIC ACID is a versatile and valuable compound with a wide range of applications in organic synthesis, pharmaceutical research, medicinal chemistry, and the chemical industry. Its unique properties and potential for further development make it an essential component in the advancement of scientific knowledge and the creation of innovative products.

InChI:InChI=1/C14H11BrO3/c15-11-6-7-13(12(8-11)14(16)17)18-9-10-4-2-1-3-5-10/h1-8H,9H2,(H,16,17)/p-1

Upstream product

• 860000-78-8 methyl 2-(benzyloxy)-5-bromobenzoate 
• 4068-76-2 5-bromo-2-hydroxy-benzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 850350-09-3 phenylmethyl 5-bromo-2-[(phenylmethyl)oxy]benzoate 
• 89-55-4 5-bromosalicyclic acid 

Downstream Products

• 1285514-20-6 5-bromo-N-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]benzamide 
• 1285514-22-8 5-bromo-2-[(phenylmethyl)oxy]-N-1H-pyrazol-4-ylbenzamide 
• 1285514-61-5 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-N-4-pyridazinylbenzamide 
• 1285514-64-8 2-[(phenylmethyl)oxy]-N-4-pyridazinyl-5-(4-pyridinyl)benzamide 
• 1285515-05-0 5-(1-methyl-1H-pyrazol-5-yl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-06-1 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-10-7 2-[(phenylmethyl)oxy]-5-(1H-pyrazol-4-yl)-N-3-pyridinylbenzamide 
• 1285515-12-9 2-[(phenylmethyl)oxy]-N-3-pyridinyl-5-(4-pyridinyl)benzamide 
• 1285515-15-2 2-[(phenylmethyl)oxy]-N,5-di-3-pyridinylbenzamide 
• 1285515-19-6 2-[(phenylmethyl)oxy]-N-3-pyridinyl-5-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]benzamide 
• 1285515-21-0 GSK-2578215A 
• 1285515-55-0 5-(2-amino-4-pyridinyl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285513-47-4 2-(benzyloxy)-5-bromo-N-(pyridazin-3-yl)benzamide 
• 1285515-07-2 5-bromo-N-(5-fluoro-3-pyridinyl)-2-[(phenylmethyl)oxy]benzamide 

Relevant academic research and scientific papers

Metal-free Synthesis of Spiro-2,2′-benzo[b]furan-3,3′-ones via PhI(OAc)2-Mediated Cascade Spirocyclization

Treating the benzyl protected 3-hydroxy-1,3-bis(2-hydroxyphenyl)prop-2-en-1-ones solely with PhI(OAc)2 (PIDA) in DCE at room temperature readily furnished the seldom studied spiro-2,2′-benzo[b]furan-3,3′-ones in satisfactory to excellent yields. The hypervalent iodine reagent enables the metal-free cascade spirocyclization resulting in the dual oxidative C?O bond formation. (Figure presented.).

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy

We describe the discovery and optimization of 5-substituted-N-pyridazinylbenzamide derivatives as potent and selective LRRK2 inhibitors. Extensive SAR studies led to the identification of compounds 18 and 23, which demonstrated good in vitro pharmacokinetic profile and excellent selectivity over 140 other kinases. Both compounds demonstrated high unbound fractions in both blood and brain. Compound 18 proved to be brain penetrant, and the high unbound fraction of compound 18 in brain enabled its in vivo efficacy in CNS, wherein a significant inhibition of LRRK2 Ser935 phosphorylation was observed in rat brain following intravenous infusion at 5 mg/kg/h.

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors

Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.